Trial site
Genesis Cancer and Blood Institute
Hot Springs, Arkansas 71913, United StatesNot linked to an institution yet
- 10running trials
- 1closed trial
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 23 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Recruiting6 trials
- Active, not recruiting3 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company2 trials
- Gilead Sciences2 trials
- Allogene Therapeutics1 trial
- Compass Therapeutics1 trial
- Eikon Therapeutics1 trial
- and 4 more
Running trials
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420· Phase 1· TerSera Therapeutics LLC· Source
Contact: Stephen Divers, MD
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Stephen Divers (principal investigator)
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· ImmunityBio, Inc.· Source
Contact: Laura Sellers, BSN, RN
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· Phase 2/3· Eikon Therapeutics· Source
Contact: Laura Sellers
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· Phase 2· Allogene Therapeutics· Source
Contact: Stephen Divers, MD (principal investigator)
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
NCT04419649· Phase 2· Takeda· Source
Contact: Lingyi Chen (principal investigator)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error